Research

Longboard Pharma was acquired by H. Lundbeck A/S on Oct 14, 2024 at about $60 per share. The deal valued Longboard at roughly $2.6 billion dollars, which made it one of the highest returning biopharma stocks of the year. That acquisition price, if closed on, will deliver an 800% return for shareholders YTD at time … Read more